A detailed history of Swiss National Bank transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 25,000 shares of MDGL stock, worth $7.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,000
Previous 24,800 0.81%
Holding current value
$7.8 Million
Previous $6.95 Million 23.64%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$212.22 - $292.96 $42,444 - $58,591
200 Added 0.81%
25,000 $5.31 Million
Q2 2024

Aug 08, 2024

BUY
$193.33 - $291.99 $270,662 - $408,786
1,400 Added 5.98%
24,800 $6.95 Million
Q1 2024

May 07, 2024

BUY
$171.37 - $283.23 $342,740 - $566,460
2,000 Added 9.35%
23,400 $6.25 Million
Q4 2023

Feb 06, 2024

SELL
$120.4 - $237.13 $84,280 - $165,991
-700 Reduced 3.17%
21,400 $4.95 Million
Q3 2023

Nov 08, 2023

SELL
$146.04 - $225.78 $817,824 - $1.26 Million
-5,600 Reduced 20.22%
22,100 $3.23 Million
Q2 2023

Aug 09, 2023

BUY
$203.88 - $312.0 $366,984 - $561,600
1,800 Added 6.95%
27,700 $6.4 Million
Q1 2023

May 10, 2023

SELL
$231.06 - $307.08 $693,180 - $921,240
-3,000 Reduced 10.38%
25,900 $6.27 Million
Q4 2022

Feb 08, 2023

BUY
$58.39 - $296.54 $40,873 - $207,578
700 Added 2.48%
28,900 $8.39 Million
Q2 2022

Aug 09, 2022

BUY
$58.04 - $100.2 $226,356 - $390,780
3,900 Added 16.05%
28,200 $2.02 Million
Q1 2022

May 09, 2022

BUY
$55.89 - $101.89 $128,547 - $234,347
2,300 Added 10.45%
24,300 $2.38 Million
Q3 2021

Nov 08, 2021

BUY
$78.35 - $105.02 $62,679 - $84,016
800 Added 3.77%
22,000 $1.76 Million
Q2 2021

Aug 06, 2021

SELL
$97.2 - $137.59 $174,960 - $247,662
-1,800 Reduced 7.83%
21,200 $2.07 Million
Q1 2021

May 07, 2021

BUY
$108.54 - $125.2 $32,562 - $37,560
300 Added 1.32%
23,000 $2.69 Million
Q3 2020

Nov 09, 2020

BUY
$99.78 - $124.21 $29,934 - $37,263
300 Added 1.34%
22,700 $2.7 Million
Q2 2020

Aug 05, 2020

BUY
$60.13 - $125.71 $354,767 - $741,689
5,900 Added 35.76%
22,400 $2.54 Million
Q1 2020

May 08, 2020

BUY
$66.76 - $93.49 $20,028 - $28,047
300 Added 1.85%
16,500 $1.1 Million
Q4 2019

Feb 06, 2020

BUY
$84.28 - $118.5 $25,284 - $35,550
300 Added 1.89%
16,200 $1.48 Million
Q3 2019

Nov 12, 2019

BUY
$84.4 - $106.53 $16,880 - $21,306
200 Added 1.27%
15,900 $1.37 Million
Q2 2019

Aug 02, 2019

BUY
$91.13 - $142.5 $154,921 - $242,250
1,700 Added 12.14%
15,700 $1.65 Million
Q1 2019

May 10, 2019

BUY
$103.48 - $143.84 $41,392 - $57,536
400 Added 2.94%
14,000 $1.75 Million
Q4 2018

Feb 13, 2019

BUY
$94.77 - $215.54 $104,247 - $237,094
1,100 Added 8.8%
13,600 $1.53 Million
Q2 2018

Aug 09, 2018

BUY
$101.55 - $313.9 $40,620 - $125,559
400 Added 3.31%
12,500 $3.5 Million
Q1 2018

May 04, 2018

BUY
$93.35 - $149.04 $18,670 - $29,808
200 Added 1.68%
12,100 $1.41 Million
Q4 2017

Feb 07, 2018

BUY
$39.35 - $97.37 $468,265 - $1.16 Million
11,900
11,900 $1.09 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.34B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.